Our Take
Boston has real money flowing into real companies, but it missed the AI wave entirely, and that's a structural problem for reputation, not just optics.
Why it matters
Venture ecosystems run on narrative and capital concentration. When a single AI round ($122 billion, per Crunchbase data) dwarfs your entire region's annual haul, you've stopped being in the same game. That affects recruit retention, LP attention, and downstream hiring across the tech sector.
Do this week
Biotech and healthcare investors: document and publicize your deployment wins and unit economics this quarter before the AI narrative completely suffocates newsflow about your sector's progress.
Boston raised $7.8 billion in 2025, but missed the AI supercycle
Startup investment in the Boston metro area totaled approximately $7.8 billion so far this year, per Crunchbase data. That puts the region on track for its strongest annual tally in about four years. Twelve companies in the greater Boston area raised rounds of $200 million or more, led by Whoop (wearable fitness technology and health platform) at $575 million in Series G funding at a $10.1 billion valuation; Cloaked (consumer privacy tools) at $375 million in Series B; and Devoted Health (Medicare plans for seniors) at $366 million across two Series F tranches.
Yet this headline masks a more pointed problem. North America venture funding hit a record $252 billion in Q1 2025 alone, per Crunchbase. More than 87% of that went to AI-related companies. The biggest generative AI names—OpenAI, Anthropic—are predominantly headquartered in the San Francisco Bay Area. Boston captured almost none of the mega-rounds that now define venture capital momentum.
By contrast, biotech and healthcare, Boston's traditional strongholds, have not participated in the funding acceleration. While no dramatic slump has occurred, the scale gap is stark. A single venture-backed AI company can close a $122 billion round; biotech round sizes cannot compete on that magnitude.
Ecosystem reputation compounds over time, and Boston lost this cycle
The Boston Globe reported this spring that Texas startups raised more venture capital than Massachusetts startups for the first time, a symbolic inflection point. Locally, concern has grown that the tech startup scene is thinning relative to other hubs.
The root issue is not Boston's ability to produce investable founders or talent. Rather, unprecedented AI capital concentration in the Bay Area and elsewhere has rewritten the comparison set. Venture capital flows to narrative and momentum. When most of the largest rounds in venture history happen outside your region in a single technology category, your relative standing shifts—even if your absolute funding is healthy.
This matters because venture ecosystems operate on perception as much as fact. LPs allocate based on where they believe the next breakout companies will emerge. Founders and senior engineers relocate based on access to capital. If Boston is associated with biotech and healthcare but not generative AI, that's not a strategic positioning; that's a missed category.
What founders and investors should do now
Boston-based biotech and healthcare founders should stop viewing AI-driven valuations as external competition and start embedding proprietary AI models into their core products. The companies winning in this market are building domain-specific AI, not general models. Devoted Health, Whoop, and others on the funding list already use AI for their core insight generation.
VCs in the region: publicize deployment wins and repeat customer metrics in healthcare and biotech with the same rigor and speed that Bay Area firms trumpet AI benchmarks. The narrative is winnable if you own it before the cycle moves again.